相关实验视频

Updated: Jan 10, 2026

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

来自Aglaia perviridis的特征性黄线具有治疗性潜在的缺血性中风

Yan-Ping Zhang¹, Ling Li¹, Qian-Qian Yin¹

¹School of Traditional Chinese Materia Medica, Key Laboratory of Innovative Traditional Chinese Medicine for Major Chronic Diseases of Liaoning Province, Key Laboratory for TCM Material Basis Study and Innovative Drug Development of Shenyang City, Shenyang Pharmaceutical University, Shenyang 110016, PR China.

The Journal of organic chemistry

|November 25, 2025

概括

Aglaia perviridis 提取物通过减少神经炎症和心脏病发作量,显示出对缺血性中风的治疗潜力. 鉴定出了新的黄化合物,其中一些可以抑制微质中的氧化生产.

科学领域:

药理学和植物化学
神经科学和神经保护神经科学和神经保护

背景情况:

缺血性中风对健康造成重大负担,需要新的治疗策略.
像Aglaia perviridis这样的传统药用植物是神经保护化合物的潜在来源.

研究的目的:

阐明Aglaia perviridis抗胰岛素中风作用的物质基础和机制.
从Aglaia perviridis中分离和描述具有潜在治疗活性的新型化合物.

主要方法:

使用中脑动脉封闭/再输 (MCAO/R) 鼠模型和LPS诱导的BV-2微质模型对原始提取物和分离化合物的评估.
包括HPLC,NMR,HR-ESI-MS,ACD/SE,DP4+分析和ECD计算在内的全面植物化学分析.
在体外生物测试以评估抗神经炎症活性,特别是氧化抑制.

主要成果:

Aglaia perviridis的乙烯酸提取物 (APE) 显示出显著的抗神经炎症活性,并减少了MCAO/R大鼠的脑梗塞体积和.
16种新型化合物和10种已知的类似物被分离和特征化,包括新型价值重组黄 (化合物1和2).
化合物5和6在BV-2细胞中强烈抑制了LPS诱导的氧化生产.

结论:

Aglaia perviridis对缺血性中风具有显著的治疗潜力,这归因于其flavagline成分.
发现了具有抗神经炎症特性的新型黄化合物,为药物发现提供了新的途径.
对这些化合物的机制和体内疗效的进一步研究是有必要的.

更多相关视频

Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model

Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model

Published on: December 9, 2018

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...